Acute GvHD (aGvHD) is the main complication of hematopoietic SCT (HSCT) during the treatment of hematological disorders. We carried out the first longitudinal study to follow the gut microbiota trajectory, from both the phylogenetic and functional points of view, in pediatric patients undergoing HSCT. Gut microbiota trajectories and short-chain fatty acid production profiles were followed starting from before HSCT and through the 3-4 months after transplant in children developing and not developing aGvHD. According to our findings, HSCT procedures temporarily cause a structural and functional disruption of the gut microbial ecosystem, describing a trajectory of recovery during the following 100 days. The onset of aGvHD is associated with specific gut microbiota signatures both along the course of gut microbiota reconstruction immediately after transplant and, most interestingly, prior to HSCT. Indeed, in pre-HSCT samples, non-aGvHD patients showed higher abundances of propionate-producing Bacteroidetes, highly adaptable microbiome mutualists that showed to persist during the HSCT-induced ecosystem disruption. Our data indicate that structure and temporal dynamics of the gut microbial ecosystem can be a relevant factor for the success of HSCT and opens the perspective to the manipulation of the pre-HSCT gut microbiota configuration to favor mutualistic persisters with immunomodulatory properties in the gut.
INTRODUCTION
Human beings share a close mutualistic relationship with 4100 trillion microbes living in their gastrointestinal tract, the human gut microbiota. 1 This immense bacterial ecosystem co-evolved as a key component of our biology, becoming a strategic factor in the maintenance of our health. Indeed, the gut microbiota exerts a central role on our nutrition 2 and, at the same time, acts as a 'microbial buffer' that limits the access of enteropathogens to the gastrointestinal tract. 3 Moreover, the gut microbiota has a function in host immunity, being strategic to the education and preservation of our immune homeostasis. 4, 5 Several key microbiota physiological functions depend on the supply of the host with pivotal microbial metabolic products, such as short-chain fatty acids (butyrate, propionate and acetate). As the final products of the gut microbiota fermentation of complex polysaccharides in the gut, short-chain fatty acids have been demonstrated to exert a central role in our physiology. These metabolites control host energy production and storage 6 and have a pivotal role in gut microbiota-host immunological cross-talk, being essential for the correct functionality of the host immune system. 7, 8 Short-chain fatty acids are also important for strengthening the host epithelial barrier as they are able to enhance the gut microbiota barrier effect 9 and stimulate the release of mucins, reinforcing the gut epithelial structure. 10 The next-generation sequencing-based surveys of the human gut microbiota allowed disclosure of the immense species-level diversity and the extraordinary degree of individual specificity of this microbial ecosystem. 11 Indeed, each subject possesses a specific subset of hundreds of species out of the thousands that constitute the human gut microbiota. In a healthy subject, this individual microbiota layout actively contributes to the host metabolic and immunological homeostasis as a mutualistic partner 12 and persists for years, showing the potential to shape many aspects of our biological features. 13 However, several circumstances can force the gut microbiota to shift from a mutualistic health-promoting configuration to a low-diversity disease-associated layout, which compromises health and consolidates the disease.
14 Gut microbiome dysbioses are involved in several inflammatory disorders, such as inflammatory bowel diseases, allergy and type II diabetes, 15 further highlighting the importance of the mutualistic interaction between our microbial counterpart and the immune system that, if compromised, affects inflammation at a systemic level. 5, 16, 17 Acute GvHD (aGvHD) is an immunological disorder that affects many organ systems, including the gastrointestinal tract, liver and skin, 18 and represents the major immuno-mediated complication of hematopoietic SCT (HSCT), limiting its success. 19, 20 In the light of the gut microbiota's potential to modulate the host systemic and local immunity, 16 the hypothesis that the maintenance of a mutualistic gut microbiota layout can be a strategic driver for preventing the onset of aGvHD has been advanced. 21 Pioneer studies exploring the link between aGvHD and resident intestinal bacteria have been carried out, [22] [23] [24] [25] [26] and available data are in general agreement in reporting the increase in opportunistic bacteria during or after aGvHD onset. However, only two of these studies were performed on adult humans, 22, 23 while the majority relied on mouse models. [24] [25] [26] Furthermore, even if there is a general agreement in reporting a deep modification of the gut 1 microbiota in humans after HSCT, [23] [24] [25] [26] [27] no longitudinal gut microbiota surveys have been carried out, and no information linking the trajectory of gut microbiota recovery after HSCT and the onset of aGvHD is available. However, suggesting the importance of the post-HSCT gut microbiota reconstruction process for the success of HSCT, the diversity of gut microbiota at engraftment has been very recently indicated as an independent predictor of mortality in adult allo-HSCT recipients. 27 In the present paper, we hypothesize a connection between the process of gut microbiota reconstruction after HSCT and aGvHD in pediatric patients and that peculiar peri-HSCT modifications of gut microbiota might impact on the probability of aGvHD onset. To this aim, here we present an observational study involving 10 pediatric patients suffering from hematological disorders and undergoing allo-HSCT, 5 of who developed aGvHD after transplantation. Gut microbiota trajectories and short-chain fatty acid production profiles were followed through the HSCT event and the following 3-4 months.
MATERIALS AND METHODS Subjects
The study was approved by the Ethics Committee of the Sant'OrsolaMalpighi Hospital-University of Bologna (ref. number 19/2013/U/Tess). After provision of informed consent, we enrolled 10 pediatric patients (mean age 8.4 years) out of a cohort of 26 who underwent HSCT for hematological disorders at the beginning of the study. Inclusion criterion was the collection of the pre-HSCT fecal sample and at least three samples after HSCT, allowing us to provide longitudinal sampling. Exclusion criteria were lack of informed consent and insufficient fecal material for bacterial DNA extraction. Demographic and transplant characteristics of the patients are summarized in Table 1 . Conditioning regimen was based on BU in all patients; no patients received TBI. BU dosage was adjusted based on a pharmacokinetic study performed following the first administration, in order to maintain a steady-state concentration between 600 and 900 ng/mL. All children were in a HEPA-filtered single room and received standard prophylactic measures to prevent infections, including levofloxacin for gut decontamination from the start of conditioning regimen to the recovery of enteral nutrition and neutrophil engraftment. 28 All patients received antibiotics for fever and neutropenia during the study period. No patient of the cohort had sepsis during the time of collection of the samples. Importantly, non-GVHD and GVHD patients had similar exposures to antibiotics during the period of stool collection: respectively, the median time of exposure to antibiotics was of 11.3 days for non-GVHD patients and 10.9 days for GVHD patients. Acyclovir and fluconazole were administered for antiviral and antifungal prophylaxis, from day − 1 and +2, respectively. 29, 30 Neutrophil and platelet engraftment were defined as occurring on the first of the three consecutive days on which the neutrophil level was ⩾ 0.5 × 10 9 /L and the blood platelets were 420 × 10 9 /L, respectively. All patients observed fasting from the day of transplant to the day of engraftment, when clinical condition allowed, as common policy of the transplantation center. Dietary restriction regimen applied to the enrolled pediatric patients is described in Supplementary Information.
Five patients out of the 10 developed aGvHD, 4 of whom had skin aGvHD (grade I-III), graded according to the Seattle grading system. 31 The patient who developed grade III skin aGvHD was treated with steroids and extracorporeal photopheresis, whereas the other three patients with grade I-II skin aGvHD received only steroids (2 mg/kg/day). One patient (subject 15) developed severe grade IV intestinal aGvHD and received steroids, infliximab and extracorporeal photopheresis.
16S rRNA gene pyrosequencing and bioinformatic analysis
Total bacterial DNA from fecal samples was extracted using the DNeasy Blood and Tissue Mini Kit (Qiagen, Duesseldorf, Germany) as reported by Salonen et al. 32 The V4 region of the 16S rRNA gene was amplified using the primers 520F and 802R, as in the study by Centanni et al.
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Pyrosequencing of pooled amplicons was performed according to the GS-FLX Titanium sequencing protocol, as described by Schnorr et al. 34 Sequencing reads were analyzed using the QIIME pipeline. 34 For bacterial taxonomy assignment, RDP-classifier (version 2.2) was used. Trimmed reads were clustered into operational taxonomic units at 97% identity level and further filtered for chimeric sequences. Alpha-diversity and rarefaction plots were computed using Shannon, PD whole tree, Chao1 and observed species metrics. Weighted and unweighted UniFrac distances were used for Principal Coordinates Analysis (PCoA), using R packages Stats and Vegan. Data separation in the PCoA was tested using a permutation test with pseudo F-ratios.
Gas chromatography-mass spectrometry determination of short-chain fatty acids in fecal samples
The analysis was carried out as reported in Schnorr et al. 34 Headspace solid-phase micro extraction was performed by using a 75-μm CarboxenTM/polydimethylsiloxane fiber (Supelco, Bellefonte, PA, USA). Analytes were desorbed into the gas chromatography (GC) injector and GC-mass spectrometry analysis was carried out on a TRACE GC 2000 Series (ThermoQuest CE Instruments, Austin, TX, USA) gas chromatograph, interfaced with GCQ Plus (ThermoQuest) mass detector with ion-trap analyzer. Phenomenex ZB-WAX (30 m × 0.25 mm ID, 0.15-μm film thickness) were used as capillary GC column. Short-chain fatty acid concentration was expressed in micromoles per gram (μmol/g) of feces. Limit of detection ranged from 4 to 68 nmol/g.
General statistics
Significant differences were assessed by Mann-Whitney U test. When appropriate, the paired test was used. Comparison of α-and β-diversity among groups was carried out by Wilcoxon signed-rank test. Kendall correlation was calculated using the function cor.test (R package Stats). P-values were corrected for multiple comparisons using the BenjaminiHochberg method; false discovery rate (FDR) o0.05 was considered as statistically significant.
RESULTS
HSCT procedures temporarily disrupt diversity, individual signature and short-chain fatty acid production of the gut microbiota The 16S rRNA gene-based phylogenetic profiles of a total of 53 stool samples, with a minimum of four time points per subject, were analyzed by 454 pyrosequencing of the V4 hypervariable region (MG-Rast accession number 11624) (Supplementary Figure  S1) . A total of 384 106 reads were obtained for a mean of 7243 ± 4557 high-quality reads per subject. Reads were clustered in 6895 operational taxonomic units (OTUs, that is, groups of sequences referring to the same species) at 97% of identity.
In order to assess the overall impact of HSCT and all the standard associated procedures on the gut microbiota of pediatric patients, we investigated the richness and diversity of the ecosystem in the pre-HSCT sample, in the first post-HSCT samples available (approximately corresponding to the engrafment date) and in the last available samples (as reference point for the patient complete recovery), which varies in sampling date due to differences in the individual path to recovery. HSCT resulted in a profound disturbance of the gut ecosystem that can be measured in the loss of about 30% in average of the pre-HSCT alpha diversity, expressed as Chao1 diversity index (mean ratio post-HSCT/pre-HSCT 0.68, FDR-corrected paired Mann-Whitney U test P = 0.0078). On the contrary, by comparing the alpha diversity of the pre-HSCT samples with the last samples available for each subject, it is evident that the ecosystem recovered the initial amount of diversity (mean ratio 0.94; Figure 1a ). The mean value of weighted UniFrac distances among pre-HSCT samples was significantly lower than that obtained among post-HSCT samples (P o 0.001), demonstrating an increase of the inter-subject gut microbiota diversity after transplantation. On the other hand, the last available samples showed a comparable degree of intersubject diversity with respect to pre-HSCT samples, further suggesting a progressive ecosystem recovery following HSCT (Figure 1b) .
In order to quantify the effect of this upsetting event on the ecosystem architecture, we quantified the loss and subsequent recovery of OTU detected. HSCT was associated with a loss of the individual signature of the gut microbiota composition since samples from the same subjects did not cluster together in multivariate analyses (Supplementary Figure S2) . Indeed, only 8.3 ± 4.9% of the OTUs in the pre-HSCT samples were conserved in the post-HSCT samples, a very small number of which 'survives' through the last available samples of each subject (2.3 ± 2.6% of the OTUs in the pre-HSCT samples), mostly assigned to the phyla Firmicutes (66.7%) and Bacteroidetes (27.5%). A small percentage of OTUs was under the limit of detection in the post-HSCT samples but 'reappeared' in the last available samples (5.9 ± 4.7%); again, these sequences were assigned mostly to Firmicutes (73.6%). The 89.3 ± 4.6% of the OTUs in the post-HSCT samples was new with The gut microbiota diversity, expressed as Chao1 index (a), and the variability among subjects (beta-diversity), expressed as unweighted Unifrac distance (b), are reported as box plots for the pre-HSCT samples (white), the first available samples after HSCT (approximating the condition at the moment of the engraftment) (light grey) and the last available samples (as reference point for the recovery of each patient) (dark grey) for each subjects.
Gut microbiota and aGvHDrespect to the pre-HSCT ecosystem, but 80.6 ± 9.9% of them were only transient (that is, not present in the last available sample of each patient). The fecal microbiota of the last available sample of each subject (that is, taken at least 51 days after HSCT) was made for 86.1 ± 9.7% of OTUs that were not present in the pre-HSCT samples in both aGvHD and non-aGvHD patients (Supplementary  Tables S1-S3 ). In order to obtain an indication of the maintenance or disruption of the functionality of the intestinal ecosystem, we quantified the short-chain fatty acid content in fecal samples (Supplementary Table S4 ). The fecal amount of short-chain fatty acids decreased by 76% after HSCT in both aGvHD and nonaGvHD subjects (mean ratio post-HSCT/pre-HSCT 0.23, FDRcorrected paired Mann-Whitney U test P = 0.016). Acetate and butyrate decreased by 64% and 77%, respectively (mean ratio post-HSCT/pre-HSCT 0.17 and 0.16, respectively; FDR-corrected paired Mann-Whitney U test P = 0.023 and 0.011, respectively), while propionate was the most reduced, with a mean loss of 86% in the first post-HSCT sample with respect to the pre-HSCT (mean ratio post-HSCT/pre-HSCT 0.14, FDR-corrected paired MannWhitney U test P = 0.018). By comparing the short-chain fatty acid amount in pre-HSCT samples with the last samples available for each subject, the gut microbiota seemed to recover the initial functionality both in terms of total short-chain fatty acid (mean ratio 1.23; paired Mann-Whitney U test P = 0.73) and propionate (mean ratio 1.09; paired Mann-Whitney U test P = 0.82) production.
aGvHD-associated gut microbiota signatures In order to highlight peculiarities of the post-HSCT reconstruction process of the gut microbiota in subjects developing and not developing aGvHD, the respective gut microbiota temporal trajectories were constructed and compared. With this goal, samples were grouped into four time intervals: pre-HSCT; 0-35 days after HSCT (interval in which engraftment occurred and, in our study, the diagnosis of the aGvHD was performed); 35-65 days after HSCT; and 465 days after HSCT (Figure 2 ). (Figure 3a) showed that samples from aGvHD subjects taken in the time interval between 0 and 35 days after HSCT, during which aGvHD emerged, clustered in the right part of the PCoA plot (Po 0.05), showing that the aGvHD onset is associated with higher values on the PCo2 axis. This is even clearer when samples from each group are ordinated by PCo2 coordinates, as inspired by Smith et al.
PCoA analysis of the weighted UniFrac distances
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( Figure 3b ): aGvHD samples taken within the 0-35 days interval shows significantly higher values of PCo2 coordinates than all the other samples (P o0.05). Interestingly, PCo2 was positively correlated (P o 0.05) to members of the Enterococcus genus and unassigned Clostridiales, while Faecalibacterium and Ruminococcus showed a negative correlation with PCo2 (P o0.05). This suggests that aGvHD involves the overgrowth of Enterococcus and Clostridiales and a corresponding decrease of Faecalibacterium and Ruminococcus. Confirming these findings, Enterococcus members were found in significantly higher relative abundance in aGvHD samples, within 0-35 days after HSCT, with respect to non-aGvHD samples (median 1.9% for aGvHD, 0.01% for nonaGvHD; P = 0.016); Enterococcus abundance in this time interval was also almost significantly higher than in pre-HSCT samples of aGvHD subjects (median 0.03%, P = 0.06), confirming the association with the aGvHD diagnosis. An opposite trend was found for the known health-promoting Faecalibacterium in aGvHD subjects (median values: pre-HSCT 12.5%, 0-35 days 0.5%; P = 0.06) but not for non-aGvHD subjects.
To better understand the capability of aGvHD to affect the overall structure of the microbiota, phylum-level temporal dynamics of gut microbiota in non-aGvHD and aGvHD subjects were constructed. Samples collected 465 days after HSCT were not taken into account in this analysis, because they were available only for a small subset of subjects. Different trends emerged for the two most abundant phyla in the intestinal ecosystem: Firmicutes and Bacteroidetes. aGvHD subjects showed a drop in Firmicutes abundance after HSCT, and then they recovered higher abundances of Firmicutes than the initial ones; such distinctive trend was not observed in non-aGvHD subjects ( Figure 4a ). More interesting, aGvHD subjects showed lower abundances of members of the Bacteroidetes in all the considered time interval than non-aGvHD subjects, and the difference was significant in pre-HSCT samples (median 0.11% for aGvHD, 14.8% for non-aGvHD; P = 0.05) (Figure 4b) . Finally, an almost significant increase in unassigned sequences (Other Bacteria) emerged in aGvHD subjects within 0-35 days after HSCT (median 1.06%), with respect to both pre-HSCT (median 0.15%, P = 0.06) and 35-65 days after HSCT (median 0.11%, P = 0.06) abundances (Figure 4c) . A tentative assignment of Other Bacteria was performed by using the newest release of Greengenes, and we were successful in Figure 3 . aGvHD microbiota signature. PCoA based on Weighted UniFrac distances of the fecal microbiota of the enrolled patients was produced (a); samples collected before HSCT (yellow), between 0 and 35 days after HSCT (orange), between 35 and 65 days after HSCT (orange), and 465 days after HSCT (dark red), from both aGvHD (circles) and non-aGvHD (tringles) subjects, are plotted. The second and third principal components (PCo2 and PCo3) are shown, each explaining 13.6% of the variance in the data set. Based on the sample ordination, significant positive and negative correlations between PCo2 and the relative abundance of some intestinal bacterial groups are reported. Average ± s.e.m. (error bars) PCo2 coordinates are shown for each group of samples (b), using the same color code of the PCoA. The significance of the difference between PCo2 coordinates of aGvHD samples taken in the 0-35 days interval after HSCT and all the other groups is indicated. assigning only 8.5% of those OTU, 65.7% of which belonged to the Firmicutes phylum, 8.6% to Proteobacteria and 8.6% to Spirochaetes.
The pre-HSCT gut ecosystem in children developing or not developing aGvHD The observation of differences in the pre-HSCT composition of the intestinal microbiota of aGvHD and non-aGvHD subjects, that is, Bacteroidetes relative abundance (Figure 4b ), led us to explore further the possibility that the gut microbiota of children who did not develop aGvHD could show some peculiarities before the upsetting procedures associated with HSCT. Indeed, the intestinal ecosystem of aGvHD subjects showed lower diversity and richness in pre-HSCT samples than that of non-aGvHD subjects (Supplementary Figure S3) . The pre-HSCT samples of aGvHD patients showed lower abundance of two important members of the Bacteroidetes phylum, with respect to the pre-HSCT samples of aGvHD patients: Bacteroides (median 6.6% for non-aGvHD patients, 0.1% for aGvHD patients; P = 0.05) and Parabacteroides (median 1.8% for non-aGvHD patients, 0% for aGvHD patients; P = 0.06). The relative abundances of Bacteroides and Parabacteroides in the pre-HSCT samples were found to be significantly correlated with the amount of propionate (Po 0.03). Also, pre-HSCT samples of the subjects who did not develop aGvHD showed almost significantly higher amounts of propionate (median 0.49 vs 0.26 μmol/g; P = 0.06) and total short-chain fatty acids (median 3.9 vs 2.7 μmol/g; P = 0.1) (Supplementary Table S4) , while the higher loads of acetate and butyrate were far from significant (median 3.0 vs. 1.8 μmol/g; P = 0.28 for acetate; median 0.34 vs 0.49 μmol/g; P = 0.41 for butyrate). Interestingly, Bacteroides was the most represented genus among the OTUs conserved from pre-HSCT to the last available sample of each subject (20%), and OTUs assigned to this genus were found to be conserved or 'reappearing' in four out of the five non-aGvHD subjects (33 OTUs in total), while only in two aGvHD subjects (12 OTUs in total) (Supplementary Tables S2 and S3) .
DISCUSSION
According to our findings, in pediatric patients, allo-HSCT and all the related standard procedures, such as the usage of prophylactic levofloxacin, are associated with a profound modification of the gut bacterial ecosystem and a disruption of its mutualistic asset. The pre-HSCT gut microbiota structure of the enrolled subjects well approximated the commonly reported healthy-like profile. 36, 37 Moreover, the pre-HSCT gut microbiota was found to be efficient in terms of short-chain fatty acid production, which is the biomarker of microbiota-host mutualistic configuration. 38 After HSCT, we witnessed a relevant change of the gut ecosystem, with a massive 'invasion' of new species and o 10% of the preexisting species being conserved. This degree of ecosystem variation largely overcomes the normal degree of temporal gut microbiota variability, which involves the change of about 40% of total species in a 5-year period. 13 The deep modification of gut microbiota after HSCT was accompanied by a loss in the abundance of health-promoting species, such as Faecalibacterium and Ruminococcus, and a damage in the mutualistic layout of the microbiota, as shown by the impaired transgenomic hostmicrobiota metabolism-here measured as the ability of gut microbiota to produce short-chain fatty acids-found in post-HSCT samples. These shifts bring to a loss of the individual fingerprint, with samples from the same subject that are not more compositionally similar to each other than samples from different patients. The great majority of the newly acquired phylotypes only temporarily invades the ecosystem and is replaced later on during the ecosystem recovery. This process is mirrored by the temporary increase of inter-subject gut microbiota diversity after transplantation, further suggesting that HSCT results in a temporary invasion of alloctonous microorganisms in the gut.
After approximately 2 months from the day of HSCT, the ecosystem recovers the initial richness and metabolic capability. Interestingly, a small percentage of bacterial species resist HSCT and are conserved throughout the whole longitudinal survey or lower their abundance under the detection limit, as a consequence of the ecosystem being upset, and 'reappear' later on. These persisting species could act as 'founders' to reconstruct a healthy-like ecosystem once conditions allow. Indeed, Bacteroides species, which are the most represented among the persisting ones, are known to act as a bacterial reservoir to maintain long-term colonization or repopulate the gut after ecosystem disruption.
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Here we have been successful in the demonstration that aGvHD and non-aGvHD subjects show a different temporal trajectory of gut microbiota ecosystem recovery after HSCT. In particular, the aGvHD onset is associated with specific dysbioses of the gut microbial ecosystem within the first month after HSCT, with a drop in the abundance of the known health-promoting Faecalibacterium and high percentages of Enterococcus, the latter being confirmed in adults by Holler et al. 23 aGvHD samples showed higher abundances of unassigned sequences, which could be indicative of a higher invasion of the ecosystem by unknown opportunistic bacteria. Most interestingly, aGvHD and non-aGvHD subjects also possess a different pre-HSCT gut microbiota composition. In particular, non-aGvHD subjects showed a pre-HSCT gut microbiota characterized by a higher abundance of members of the Bacteroidetes phylum, in particular Parabacteroides and Bacteroides. This gut microbiota signature is projected in the distinctive trajectory of post-HSCT gut microbiome reconstruction, allowing us to hypothesize a role for gut microbiota in the success of HSCT. Interestingly, Bacteroidetes are known to produce propionate from dietary fiber 40 and were correlated with the pre-HSCT fecal concentration of propionate in this study. This gut microbiota product has the potential to exert systemic immunomodulatory functions, such as promotion of extrathymic regulatory T cell generation and homing to the gut, 8 as well as enhancement of hematopoiesis of DC precursors with a low ability to activate the allergy-related T helper type 2 cells. 17 The challenging nature of the enrollment of ill children and the difficulty in obtaining compliance for the collection of fecal samples during a highly sensitive period of illness limited the number of patients studied in the present paper, which should be considered as a pilot study in the field. Nonetheless, the relevance of this study, as well as the importance of future development of the same approach, become evident when considering the increasing number of pediatric patients who can be cured by allo-HSCT and the relevance of aGvHD as a potential lifethreatening event limiting this procedure. 42 Even if covariates such as the impact of pretransplant chemotherapy, underlying malignancy and differences in paediatric age were not considered here and will need a much larger cohort to be taken into account, our study indicates, with the necessary caution, the gut microbiota's structural and functional layout as a possible factor involved in aGvHD. We hypothesize that a pre-HSCT gut microbiota configuration enriched in propionateproducing Bacteroidetes could favor a mutualistic trajectory of ecosystem recovery after transplantation, positively affecting the immune system homeostasis at a systemic level, thanks to the propionate immunomodulatory capability, and consequently lowering the risk of aGvHD onset. In this scenario, it could be important to seek for strategies to manipulate the pre-HSCT gut microbiota layout. For instance, fiber-rich diet can be utilized to favor short-chain fatty acid-producing groups, such as Bacteroidetes members, that might be involved in the modulation of the immunological recovery after HSCT and, possibly, impact the probability of escaping aGvHD.
